Article and Video CATEGORIES

Cancer Journey

Search By

Chief of Hematology/Oncology and Medical Director at Memorial Cancer Institute, and Clinical Associate Professor of Medicine at Florida International University

Chief of Hematology/Oncology
Medical Director of Memorial Cancer Institute

Lung Cancer Video Library - Spanish Language: Video #20 Treating Early Stage Non-Small Cell Lung Cancer (NSCLC)
Anonymous
Author
Luis Raez, MD FACP FCCP
 

 

TRANSCRIPTS - Spanish and English
 

Tratamiento para el estadio temprano del cáncer de pulmón de células no pequeñas

A veces es difícil recordar cual es el estadio I o II y uno se puede perder hablando del estadio. En general, el estadio I y II son sencillos porque son tumores que son confinados al pulmón, son tumores que no han invadido el mediastino y son operables. Para el estadio I y II lo que haces es cirugía como primera intervención y dependiendo de los hallazgos patológicos después de la cirugía, hacemos quimioterapia porque muchas veces a pesar de que hemos resecado tumores pequeños, como del estadio IB que son tumores pequeños de 3.5 cm, hay un riesgo de recurrencia y mortalidad grande.

Desafortunadamente, incluso en la cirugía más perfecta que es el estadio IA que pueden ser tumores de 2cm de cáncer de pulmón, los pacientes no necesariamente se curan después de los 5 años. Vemos que una parte del 10 al 20% igual van a morir por la recurrencia del cáncer de pulmón, he ahí la necesidad de dar quimioterapia.

Ahora, la quimioterapia tampoco es para todos. Hay mucha evidencia clínica que para estadio II no es discusión, se da la quimioterapia de 4 ciclos de cisplatino más el agente de elección como etopósido, pemetrexed, vinorelbina, taxanes. Después de eso, solo es observación y seguimiento del paciente.

Para estadio IA, el beneficio de la quimioterapia no existe o no está documentado, por eso no hacemos quimioterapia. Por eso es un área de mucha investigación para tratar de clasificar que pacientes tienen un riesgo alto que justifique quimioterapia u otra intervención y que pacientes no. 


Treatment for early stage non-small cell lung cancer

Sometimes it’s difficult to remember which cases are stage I and which one are stage II, one can get lost talking about the stage. In general, stage I and II are simple because the tumor is confined to the lung, they are tumors that have not invaded the mediastinum and are surgically removed. For stage I and II, what we have to is surgery as first intervention and depending on the pathological findings, we can then do a surgery. We do chemotherapy because sometimes despite the small resected tumors like in stage IB (tumors smaller than 3.5 cm), there is a high risk of recurrence and mortality.

Unfortunately, even in the most perfect surgery in stage IA, than can be tumors of over 2 cm, patients don’t necessarily heal after 5 years. We see that a part of 10 to 20% will still die for lung cancer recurrence, so we need to give chemotherapy.

Now, chemotherapy is not for everybody. There is clinical evidence that for stage II chemotherapy the option is to give 4 cycles of cisplatin and the choice agent like etoposide, pemetrexed, vinorelbine or taxanes. After that, it’s only observation and the follow up of the patient.

Next Previous link

Previous PostNext Post

Related Content

Online Community

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...

Hi Stan!  So good to hear from you.  I'm sorry for the late response.  I too have been out of town with family and missed your post, probably because I was...

It is so good to hear from you!  And I am so happy to hear that your holidays have been good and that you are doing well.  It sounds like your...

Recent Comments

JOIN THE CONVERSATION
Biomarkers
By JanineT GRACE … on
Radiation Therapy
By JanineT GRACE … on
Oligometastatic vs Oligoprogression
By JanineT GRACE … on
Hi Stan!! and happiest of holidays!
By dbrock on